Abstract
Introduction: In recent years, several new treatments for metastatic prostate cancer have shown an overall survival benefit in randomised trials [1–3]. Palliation of symptoms is an additional important goal of management for these patients. Two NICE-approved agents that have evidence supporting improved palliation of pain and reduced incidence of skeletal events are abiraterone and zoledronic acid [1,4]. The aim of this retrospective analysis was to assess any effect of increasing use of these agents on our centre’s use of palliative radiotherapy for bone metastasis-related symptoms.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
